© 2023 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.
Top oncology experts share how they deliver these therapies to patients in need.
Michael Bishop, MD, professor of medicine and director of the cellular therapy program at UChicago Medicine, has spent his entire career trying to provide options for patients who don’t have options. That’s why it’s so rewarding to bring CAR T-cell therapy to his patients.
“Nobody likes to watch a patient die, so trying to provide that opportunity for a cure…trying to set this up,” Bishop says. This was easy. It was a work of love. I’ve never used that term at work before.”
Bishop pushed to get UChicago Medicine involved in clinical trials for Kymriah (tisagenlecleucel) for treating children and young adults with an untreatable form of acute lymphoblastic leukemia and Yescarta (axicabtagene ciloleucel) for use in adults with certain types of non-Hodgkin lymphoma.
Kymriah received FDA approval in August 2017 for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia that’s refractory or in second or later relapse. In October 2017, FDA approved Yescarta for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.
According to the FDA, diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma in adults. There are approximately 72,000 new cases of non-Hodgkin lymphoma diagnosed in the United States each year; diffuse large B-cell lymphoma comprises approximately one in three newly diagnosed cases.
Acute lymphoblastic leukemia accounts for less than half of 1% of all cancers in the United States, according to the American Cancer Society; an average person’s lifetime risk of getting acute lymphoblastic leukemia is approximately 1 in 1,000, and the risk is slightly higher for males than in females.
What follows is advice from Bishop and other experts for healthcare executives who want to deliver these therapies.
1. Make a strong case to the C-suite
First, think about what’s important to your executive team, says Luca Capicchioni, program manager for stem cell transplant and cellular therapy at UChicago Medicine. “They’re probably fielding hundreds of requests-very frequently for more resources-so you have to think about this from their perspective.”
Academic medical centers should make a strong case about the research and teaching possibilities with providing CAR T-cell treatment, he advises. That’s in addition to the impact on patient care.
Parameswaran Hari, MD, hematologist/oncologist and chief of the hematology and oncology division at Froedtert Hospital and Medical College of Wisconsin Clinical Cancer Center, agrees. “If the hospital isn’t investing in CAR T-cell therapy, that’s short-sighted. [The hospital] is going to be left behind,” he says. And that could mean losing patients to other provider organizations.
2. Be clear about your mission
“It’s not about developing a new therapy,” says Bishop at UChicago Medicine. “It’s not just another infusion or another chemotherapy. It’s about transforming the entire patient process, from the moment they get on the phone or they’re referred by their physician through survivorship.” It’s important to make sure that everyone-such as the nurses and the intake team-knows that the healthcare organization is providing CAR T-cell therapy and what these teams must do to support patients, he adds.
Related: Cancer and Ethnicity
Providers also need to secure accreditation by the Foundation for the Accreditation of Cellular Therapy (FACT), says Capicchioni. In part, the accreditation required additional work by the quality manager on his team to review policies and procedures.
A point of encouragement from Hari of Froedtert? Facilities that have already received accreditation to provide stem-cell treatments have some of this infrastructure already in place.
While there’s a reduced chance of side effects with CAR T-cell therapy when compared with chemotherapy, serious side effects do occur, he added. Serious side effects can include liver failure, activation of an autoimmune disease, colitis, or death.
Treating these side effects requires the oncology team to establish good relationships with intensive care, neurology, infectious disease, and pharmacy teams, says Lizamarie Bachier, MD, professor of medicine at Montefiore Einstein Center for Cancer Care.
At Montefiore Medical Center in the Bronx, New York, the minimum required stay for patients receiving CAR T-cell treatment is two weeks. That’s because most of the patients who experience a toxicity associated with the treatment do so within two weeks.
The toxicities associated with CAR T-cell therapy can be adequately managed, says Bachier. To respond, oncology providers must ensure that clinicians have guides for managing the toxicities, particularly in the emergency department. Pharmacy colleagues also need to make available steroids and tocilizumab (Actmera), which is indicated for the treatment of CAR T-cell-induced severe or life-threatening cytokine release syndrome in adults and pediatric patients 2 years of age and older, per the FDA.
Aine Cryts is a writer based in Boston.